ERBB2 and breast carcinoma: Although HER2+ tumors are more common among patients with inflammatory breast cancer (36) and, as triple negative, HER2+ breast cancer is typically associated with more pronounced local inflammation, no connection was found between HER-2 positivity and tissue expression or serum level of IL-17, even in earlier studies (24, 42).